Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Capecitabine × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 18 Stomach Neoplasms 11 Adenocarcinoma Of Esophagus 7 Neoplasm Metastasis 6 Triple Negative Breast Neoplasms 5 Rectal Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Esophageal Neoplasms 5 Colorectal Neoplasms 5 Colonic Neoplasms 3 Adenocarcinoma 3 Pathologic Complete Response 2 Neoplasms 2 Nasopharyngeal Carcinoma 2 Gallbladder Neoplasms 2 Cholangiocarcinoma 2 Anus Neoplasms 2 Somatostatinoma 1 Resectable Colon Cancer 1 Recurrence 1 Pancreatic Intraductal Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasm, Residual 1 Meningeal Neoplasms 1 Locally Advanced Rectal Cancer With Liver Metastases 1 Locally Advanced Rectal Cancer 1 Klatskin Tumor 1 Insulinoma 1 HIV Infections 1 HER2-positive Gastric Cancer 1

Interventions

pertuzumab 2 Trastuzumab 2 tucatinib 1 pyrotinib 1 Paclitaxel 1 Docetaxel 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡